Stay Informed with Annovis News, Information, Activities and Other Updates

Corporate News

• May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
• April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
• April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
• March 23, 2022Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
• March 18, 2022Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
• March 8, 2022Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
• March 3, 2022Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
• January 25, 2022Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
• January 10, 2022Annovis Bio Enhances Leadership Team with Two Senior Appointments
• January 5, 2022Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
• December 5, 2023Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
• December 1, 2023Annovis Bio Appoints Andrew Walsh as Vice President Finance
• November 27, 2023Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
• November 8, 2023Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
• November 2, 2023Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
• October 31, 2023Annovis Bio Announces Pricing of $7.5 Million Public Offering
• October 30, 2023Annovis Bio Announces Launch of Proposed Public Offering
• October 30, 2023Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
• October 24, 2023Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
• October 12, 2023Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
• August 15, 2023Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
• July 18, 2023Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
• June 27, 2023Annovis Bio Announces the Filing of a Groundbreaking Patent
• June 20, 2023Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
• June 8, 2023Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
• May 11, 2023Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
• April 27, 2023Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
• April 20, 2023ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST
• April 19, 2023ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST
• April 13, 2023ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS
• April 11, 2023ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
• April 3, 2023Annovis Bio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
• March 22, 2023ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES
• February 8, 2023Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
• February 1, 2023Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
• January 25, 2023ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
• January 6, 2023Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team
• November 8, 2022Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update
• October 20, 2022Annovis Bio to Present at the 2022 ThinkEquity Investor Conference
• October 11, 2022Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease
• October 6, 2022Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
• September 29, 2022Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference
• September 13, 2022Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
• September 8, 2022Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders
• August 29, 2022Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
• August 24, 2022Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
• August 8, 2022Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
• August 1, 2022Annovis Bio to Participate on Alzheimer's Association International Conference Panel
• July 14, 2022Annovis Bio to Present at the Alzheimer's Association International Conference
• July 7, 2022Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
• June 9, 2022Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
• December 14, 2021Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
• November 15, 2021Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
• November 12, 2021Annovis Bio Presented at the 14th Clinical Trials on Alzheimer’s Disease Conference
• November 9, 2021Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
• November 2, 2021Annovis Bio to Present at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
• October 5, 2021Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’s Disease
• September 24, 2021Annovis Bio to Present at the Cantor Global Healthcare Conference
• September 10, 2021Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
• September 3, 2021Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report®
• August 25, 2021Annovis Bio to Present at Biomarkers for Alzheimer’s Disease Summit 2021
• August 11, 2021Annovis Bio Completes Dosing of Parkinson’s Disease Patients with ANVS401 in Phase 2a Clinical Trial
• July 30, 2021Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease
• July 28, 2021Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference
• July 23, 2021Annovis Bio to Present New Data at 2021 Alzheimer’s Association International Conference
• July 20, 2021Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study
• July 2, 2021Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials
• July 1, 2021Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO
• June 24, 2021Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards
• June 8, 2021Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study
• June 3, 2021Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
• June 1, 2021Annovis Bio’s ANVS401 Improves Speed and Accuracy in Alzheimer’s and in Parkinson’s Patients
• May 28, 2021Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
• May 27, 2021Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
• May 23, 2021Annovis Bio, Inc. Announces Pricing of Public Offering
• May 21, 2021Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
• May 21, 2021Annovis Bio Announces Positive Phase 2 Data – ANVS401 Improves Cognition in Alzheimer’s Disease - Patients’ Cognition Improved 3.3 Points on ADAS-Cog11
• May 20, 2021Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
• May 20, 2021Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
• May 18, 2021Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research
• May 13, 2021Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome
• May 11, 2021Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
• May 10, 2021Annovis Bio to Ring Closing Bell at the New York Stock Exchange
• May 6, 2021Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
• April 29, 2021Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
• April 15, 2021Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
• March 17, 2021Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
• March 16, 2021Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
• March 11, 2021Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage Studies
• March 11, 2021Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit 
• March 10, 2021Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury
• March 9, 2021Annovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference
• February 16, 2021Annovis Bio to Present at the BIO CEO & Investor Digital Conference
• February 4, 2021Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
• February 2, 2021Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
• January 5, 2021Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference
• December 17, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
• December 15, 2020Annovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences
• December 7, 2020Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020
• December 3, 2020Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference
• November 16, 2020Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
• November 12, 2020Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
• November 2, 2020Annovis Bio CEO to Present at Meridian Clinical Trials Summit
• October 29, 2020Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease after COVID-Related Delay
• October 22, 2020Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award
• October 20, 2020Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair
• October 15, 2020Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
• October 12, 2020Annovis Bio to Present at the 2020 BIO Investor Forum
• September 29, 2020Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
• September 3, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
• September 1, 2020Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial
• August 20, 2020Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases
• July 23, 2020Annovis Bio CEO Appears on Executive Leaders Radio Program
• July 20, 2020Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
• July 7, 2020Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
• June 16, 2020Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
• June 9, 2020Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
• June 2, 2020Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
• June 1, 2020Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
• May 27, 2020Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19
• May 1, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
• April 30, 2020Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68  Parkinson’s and Alzheimer’s Patients
• April 23, 2020Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
• April 13, 2020Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
• February 27, 2020Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
• February 20, 2020Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
• February 13, 2020Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
• January 31, 2020Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
• January 29, 2020Annovis Bio Announces Pricing of Initial Public Offering
• July 09, 2019Annovis Hires Jeff McGroarty as CFO
• June 24, 2019Annovis Name Change
• June 02, 2016QR News Release ADCS SILK Study
• May 06, 2016QR News Release Series A Financing
• January 05, 2015QR Pharma Chairman and Board
• October 09, 2013QR News Release US Army Grant Award
• March 06, 2012QR MJFF Funding
• November 10, 2011QR News Release Iris Newman Award
• December 02, 2010QR News Release IND for BNC Approved
• August 25, 2010Biz Life Science Awards
• July 14, 2010QR News Release Posiphen Clinical Data
• April 26, 2010CityBiz $2 million funding from BioAdvance and private investors Citibizlist
• February 24, 2010News Release Down Syndrome Patent
• June 08, 2009Philadelphia Inquirer QR Board
• November 20, 2008QR Newsrelease TPTX 2ndRelease ​